Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blue Jet HealthcareBOM:544009 +0.25%65 PB Ratio is 7.52 as of Aug. 27, 2026, which is 12% below its 10-year median of 8.50. GuruFocus rates BOM:544009 with a GF Score™ of 65/100 and a GF Value™ of ₹526.27 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 1,212 Biotechnology companies, Blue Jet Healthcare ranks worse than 80.12% on this metric.
The historical rank and industry rank for Blue Jet Healthcare's PB Ratio or its related term are showing as below:
BOM:544009'
s PB Ratio Range Over the Past 10 Years
Min: 4.55 Med: 8.5 Max: 14.61
Current: 7.52
During the past 6 years, Blue Jet Healthcare's highest PB Ratio was 14.61. The lowest was 4.55. And the median was 8.50.
BOM:544009's PB Ratio is ranked worse than 80.12% of 1212
companies
in the Biotechnology industry
Industry Median: 2.95
vs BOM:544009: 7.52
During the past 12 months, Blue Jet Healthcare's average Book Value Per Share Growth Rate was 20.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 25.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 31.10% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Blue Jet Healthcare was 35.50% per year. The lowest was 25.90% per year. And the median was 29.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Blue Jet Healthcare PB Ratio Related Terms
Blue Jet Healthcare PB Ratio Historical Data
* Premium members only.
The historical data trend for Blue Jet Healthcare's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544009 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Blue Jet Healthcare's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blue Jet Healthcare PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Blue Jet Healthcare's PB Ratio distribution charts can be found below:
* The bar in red indicates where Blue Jet Healthcare's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Blue Jet Healthcare (BOM:544009) has a PB Ratio of 7.52 as of Aug. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Blue Jet Healthcare and its competitors. This is 12% below median its historical median of 8.50. Over the past decade, Blue Jet Healthcare's PB Ratio has ranged from 4.55 to 14.61. According to the industry distribution chart, Blue Jet Healthcare ranks #971 out of 1212 companies in the Biotechnology industry, placing it in the top 80.1%.
Is Blue Jet Healthcare's PB Ratio too high?
Blue Jet Healthcare's current PB Ratio of 7.52 is 12% below median its 10-year median of 8.50. Over the past 10 years, this metric has ranged from a low of 4.55 to a high of 14.61. The Biotechnology industry median PB Ratio is 2.95. Blue Jet Healthcare's value of 7.52 is 154.9% above this industry median. Based on the distribution chart, Blue Jet Healthcare ranks #971 out of 1212 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Blue Jet Healthcare has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Blue Jet Healthcare's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Blue Jet Healthcare ranks #971 out of 1212 companies for PB Ratio. This places Blue Jet Healthcare in the lower half of its industry. The industry median PB Ratio is 2.95. Blue Jet Healthcare's value of 7.52 is 154.9% above this benchmark. Historically, Blue Jet Healthcare's own PB Ratio has ranged from 4.55 to 14.61 over the past decade. While the company's 10-year median is 8.50 vs. the industry median of 2.95, Blue Jet Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,212 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blue Jet Healthcare's current PB Ratio of 7.52 is 154.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Blue Jet Healthcare and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blue Jet Healthcare's current PB Ratio is 7.52, which is 12% below median its own 10-year median of 8.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blue Jet Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Blue Jet Healthcare (BOM:544009) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹526.27, compared to a current price of ₹589.75 — trading 12.1% above its estimated fair value. The current PB Ratio is 7.52, which is 12% below median its 10-year median of 8.50 and 154.9% above the Biotechnology industry median of 2.95. Blue Jet Healthcare's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Blue Jet Healthcare (BOM:544009), the current PB Ratio is 7.52 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blue Jet Healthcare (BOM:544009) Overvalued in 2026?
Based on GuruFocus' analysis, Blue Jet Healthcare stock appears to be overvalued.
The current stock price of ₹589.75 is trading 12.1% above its estimated GF Value™ of ₹526.27.
GuruFocus considers Blue Jet Healthcare to be Modestly Overvalued.
Key valuation signals for BOM:544009:
PB Ratio: 7.52 (12% below median its 10-year median of 8.50)
GF Value™: ₹526.27 vs. price of ₹589.75 (12.1% above fair value)
Industry Position: 154.9% above the Biotechnology median (#971 of 1212)
No single metric tells the full story. See the BOM:544009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blue Jet Healthcare Ltd is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare Products. The operations of the company are organized in three product categories which are contrast media intermediates, artificial sweeteners, pharma intermediates, and active pharmaceutical ingredients. Geographically, it operates in Norway, France, India and Rest of the World.
65GF Score
Get the complete analysis for BOM:544009
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544009 has been successfully added to your 
